Summary:
A Double-Blind, Double-Dummy Phase 2 Randomized Study to evaluate the efficacy and safety of Ruxolitinib versus Anagrelide in subjects with Essential Thrombocythemia who are resistant to or Intolerant of Hydroxyurea
Qualified Participants Must:
• Men and women aged 18 or older
•
Subjects diagnosed with ET (essential thrombocythemia)
•
Known status of JAKV617F mutation
Qualified Participants May Receive:
Compensation for their time and trtavel as well as all eligible participants will receive study treatment and medication at no cost.